Literature DB >> 18398839

Persistent downregulation of the pancarcinoma-associated epithelial cell adhesion molecule via active intranuclear methylation.

Bernardina T F van der Gun1, Reinhold Wasserkort2, Amélie Monami3, Albert Jeltsch4, Tamás Raskó5, Krystyna Ślaska-Kiss5, Rene Cortese2, Marianne G Rots1, Lou F M H de Leij1, Marcel H J Ruiters1, Antal Kiss5, Elmar Weinhold3, Pamela M J McLaughlin1.   

Abstract

The epithelial cell adhesion molecule (EpCAM) is expressed at high levels on the surface of most carcinoma cells. SiRNA silencing of EpCAM expression leads to reduced metastatic potential of tumor cells demonstrating its importance in oncogenesis and tumor progression. However, siRNA therapy requires either sequential delivery or integration into the host cell genome. Hence we set out to explore a more definite form to influence EpCAM gene expression. The mechanisms underlying the transcriptional activation of the EpCAM gene, both in normal epithelial tissue as well as in carcinogenesis, are poorly understood. We show that DNA methylation plays a crucial role in EpCAM expression, and moreover, active silencing of endogenous EpCAM via methylation of the EpCAM promoter results in a persistent downregulation of EpCAM expression. In a panel of carcinoma derived cell lines, bisulfite analyses showed a correlation between the methylation status of the EpCAM promoter and EpCAM expression. Treatment of EpCAM-negative cell lines with a demethylating agent induced EpCAM expression, both on mRNA and protein level, and caused upregulation of EpCAM expression in an EpCAM-positive cell line. After delivery of the DNA methyltransferase M.SssI into EpCAM-positive ovarian carcinoma cells, methylation of the EpCAM promoter resulted in silencing of EpCAM expression. SiRNA-mediated silencing remained for 4 days, after which EpCAM re-expression increased in time, while M.SssI-mediated downregulation of EpCAM maintained through successive cell divisions as the repression persisted for at least 17 days. This is the first study showing that active DNA methylation leads to sustained silencing of endogenous EpCAM expression. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18398839     DOI: 10.1002/ijc.23476

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Genome-wide changes accompanying the knockdown of Ep-CAM in retinoblastoma.

Authors:  Moutushy Mitra; Mallikarjuna Kandalam; Rama Shanker Verma; Krishnan UmaMaheswari; Subramanian Krishnakumar
Journal:  Mol Vis       Date:  2010-05-11       Impact factor: 2.367

2.  Targeted DNA methylation by a DNA methyltransferase coupled to a triple helix forming oligonucleotide to down-regulate the epithelial cell adhesion molecule.

Authors:  Bernardina T F van der Gun; Maria Maluszynska-Hoffman; Antal Kiss; Alice J Arendzen; Marcel H J Ruiters; Pamela M J McLaughlin; Elmar Weinhold; Marianne G Rots
Journal:  Bioconjug Chem       Date:  2010-07-21       Impact factor: 4.774

3.  Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood.

Authors:  Stephen D Mikolajczyk; Lisa S Millar; Pavel Tsinberg; Stephen M Coutts; Maryam Zomorrodi; Tam Pham; Farideh Z Bischoff; Tony J Pircher
Journal:  J Oncol       Date:  2011-04-19       Impact factor: 4.375

4.  Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancer.

Authors:  B T F van der Gun; M L de Groote; H G Kazemier; A J Arendzen; P Terpstra; M H J Ruiters; P M J McLaughlin; M G Rots
Journal:  Br J Cancer       Date:  2011-06-21       Impact factor: 7.640

5.  Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells.

Authors:  Suneetha Nunna; Richard Reinhardt; Sergey Ragozin; Albert Jeltsch
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

6.  From Bioengineering to CRISPR/Cas9 - A Personal Retrospective of 20 Years of Research in Programmable Genome Targeting.

Authors:  Albert Jeltsch
Journal:  Front Genet       Date:  2018-01-26       Impact factor: 4.599

7.  Experimental mitochondria-targeted DNA methylation identifies GpC methylation, not CpG methylation, as potential regulator of mitochondrial gene expression.

Authors:  Monique G P van der Wijst; Amanda Y van Tilburg; Marcel H J Ruiters; Marianne G Rots
Journal:  Sci Rep       Date:  2017-03-14       Impact factor: 4.379

8.  Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer.

Authors:  Sabine Stolzenburg; Marianne G Rots; Adriana S Beltran; Ashley G Rivenbark; Xinni Yuan; Haili Qian; Brian D Strahl; Pilar Blancafort
Journal:  Nucleic Acids Res       Date:  2012-05-04       Impact factor: 16.971

Review 9.  Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes.

Authors:  Marloes L de Groote; Pernette J Verschure; Marianne G Rots
Journal:  Nucleic Acids Res       Date:  2012-09-21       Impact factor: 16.971

Review 10.  Revisiting the Roles of Pro-Metastatic EpCAM in Cancer.

Authors:  M Aiman Mohtar; Saiful Effendi Syafruddin; Siti Nurmi Nasir; Teck Yew Low
Journal:  Biomolecules       Date:  2020-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.